Trial Profile
A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 11 Jul 2013 The company have no further plans for studies in pancreatic cancer at this time, according to the fiscal year report issued by Peregrine Pharmaceuticals in July 2013.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2013 Results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2013, according to a Peregrine Pharmaceuticals media release.